Hændelsesraten for hoftefrakturer var 1, 44% for patienter behandlet med Aclasta sammenlignet med 2, 49% for patienter behandlet med placebo.
The hip fracture event rate was 1.44% for Aclasta-treated patients compared to 2.49% for placebo-treated patients.